全文获取类型
收费全文 | 32236篇 |
免费 | 1650篇 |
国内免费 | 167篇 |
专业分类
耳鼻咽喉 | 383篇 |
儿科学 | 586篇 |
妇产科学 | 326篇 |
基础医学 | 4160篇 |
口腔科学 | 916篇 |
临床医学 | 2317篇 |
内科学 | 7865篇 |
皮肤病学 | 558篇 |
神经病学 | 2532篇 |
特种医学 | 1242篇 |
外科学 | 5066篇 |
综合类 | 215篇 |
预防医学 | 1219篇 |
眼科学 | 507篇 |
药学 | 2803篇 |
中国医学 | 69篇 |
肿瘤学 | 3289篇 |
出版年
2023年 | 156篇 |
2022年 | 321篇 |
2021年 | 564篇 |
2020年 | 272篇 |
2019年 | 396篇 |
2018年 | 542篇 |
2017年 | 431篇 |
2016年 | 512篇 |
2015年 | 542篇 |
2014年 | 725篇 |
2013年 | 917篇 |
2012年 | 1318篇 |
2011年 | 1443篇 |
2010年 | 824篇 |
2009年 | 730篇 |
2008年 | 1269篇 |
2007年 | 1313篇 |
2006年 | 1348篇 |
2005年 | 1452篇 |
2004年 | 1359篇 |
2003年 | 1348篇 |
2002年 | 1388篇 |
2001年 | 1227篇 |
2000年 | 1369篇 |
1999年 | 1202篇 |
1998年 | 420篇 |
1997年 | 312篇 |
1996年 | 314篇 |
1995年 | 277篇 |
1994年 | 256篇 |
1993年 | 252篇 |
1992年 | 805篇 |
1991年 | 722篇 |
1990年 | 736篇 |
1989年 | 781篇 |
1988年 | 713篇 |
1987年 | 640篇 |
1986年 | 608篇 |
1985年 | 573篇 |
1984年 | 449篇 |
1983年 | 332篇 |
1982年 | 190篇 |
1981年 | 154篇 |
1980年 | 160篇 |
1979年 | 286篇 |
1978年 | 223篇 |
1977年 | 173篇 |
1974年 | 166篇 |
1971年 | 153篇 |
1969年 | 173篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Yu Sato Akiomi Yoshihisa Yusuke Kimishima Takatoyo Kiko Shunsuke Watanabe Yuki Kanno Satoshi Abe Makiko Miyata Takamasa Sato Satoshi Suzuki Masayoshi Oikawa Atsushi Kobayashi Takayoshi Yamaki Hiroyuki Kunii Kazuhiko Nakazato Takafumi Ishida Yasuchika Takeishi 《The Canadian journal of cardiology》2018,34(1):80-87
Background
It is widely recognized that overt hyper- as well as hypothyroidism are potential causes of heart failure (HF). Additionally it has been recently reported that subclinical hypothyroidism (sub-hypo) is associated with atherosclerosis, development of HF, and cardiovascular death. We aimed to clarify the effect of sub-hypo on prognosis of HF, and underlying hemodynamics and exercise capacity.Methods
We measured the serum levels of thyroid stimulating hormone (TSH) and free thyroxine (FT4) in 1100 consecutive HF patients. We divided these patients into 5 groups on the basis of plasma levels of TSH and FT4, and focused on euthyroidism (0.4 ≤ TSH ≤ 4 μIU/mL and 0.7 ≤ FT4 ≤ 1.9 ng/dL; n = 911; 82.8%) and sub-hypo groups (TSH > 4 μIU/mL and 0.7 ≤ FT4 ≤ 1.9 ng/dL; n = 132; 12.0%). We compared parameters of echocardiography, cardiopulmonary exercise testing, and cardiac catheterization, and followed up for cardiac event rate and all-cause mortality between the 2 groups.Results
Although left ventricular ejection fraction did not differ between the 2 groups, the sub-hypo group had lower peak breath-by-breath oxygen consumption and higher mean pulmonary arterial pressure than the euthyroidism group (peak breath-by-breath oxygen consumption, 14.0 vs 15.9 mL/min/kg; P = 0.012; mean pulmonary arterial pressure, 26.8 vs 23.5 mm Hg, P = 0.020). In Kaplan-Meier analysis (mean 1098 days), the cardiac event rate and all-cause mortality were significantly higher in the sub-hypo group than those in the euthyroidism group (log rank, P < 0.01, respectively). In Cox proportional hazard analysis, sub-hypo was a predictor of cardiac event rate and all-cause mortality in HF patients (P < 0.05, respectively).Conclusions
Sub-hypo might be associated with adverse prognosis, accompanied by impaired exercise capacity and higher pulmonary arterial pressure, in HF patients. 相似文献992.
Kazuo Umemura Shinji Watanabe Kazunao Kondo Hisakuni Hashimoto Mitsuyoshi Nakashima 《Atherosclerosis》1997,130(1-2):11-16
The inhibitory effect of prostaglandin E1, which has an anti-platelet action and a vasodilating action via intracellular cyclic AMP elevation, was studied on intimal thickening in the rat femoral artery. A segment of the femoral artery was occluded by a platelet and fibrin-rich thrombus due to photochemical reaction between systemically administered Rose Bengal and transluminal green light which causes endothelial injury followed by platelet adhesion and aggregation at the site of photochemical reaction. Three weeks after endothelial injury, intimal thickening occurred at the irradiated site. Prostaglandin E1 (0.3 μg/kg per min), administered as a continuous infusion 10 min before photochemical reaction significantly (P<0.05) prolonged the time to occlusion of the femoral artery. In a separate experiment, prostaglandin E1 (0.3 μg/kg per min) administered as a continuous infusion for 7 days just after endothelial injury significantly (P<0.05) inhibited intimal thickening compared with a control group. In cultured rat-derived vascular smooth muscle cells, prostaglandin E1 produced concentration-dependent inhibition of migration and proliferation, stimulated by platelet-derived growth factor. These results suggest that prostaglandin E1 may be effective in preventing vascular restenosis after vascular surgery and angioplasty. 相似文献
993.
994.
995.
Tamotsu Yabumoto Sohee Shin Tsuneo Watanabe Yusuke Watanabe Toru Naka Kazuo Oguri Toshio Matsuoka 《Journal of Physical Therapy Science》2015,27(9):3023-3025
[Purpose] Strength training is recommended for children with cerebral palsy. However, it
is difficult for moderately impaired children with cerebral palsy, who require crutches
for ambulation, to participate in this type of training. The purpose of this study was to
investigate whether whole-body vibration training is an effective method of strengthening
in a moderately impaired child with cerebral palsy. [Subject and Methods] This report
describes an 8-year-old Japanese boy with cerebral palsy, who was ambulatory with
crutches. The subject participated in physical therapy twice a week for 5 weeks.
Whole-body vibration training was selected to complement the standing practice. The
patient’s crutch-walking ability, gross motor function, and spasticity were evaluated.
[Results] The number of steps and walking duration were reduced in a 5-m walk test with
crutches and gross motor function was improved. Further, the spasticity was reduced.
[Conclusion] Whole-body vibration training is an effective physical therapy intervention
in moderately impaired children with cerebral palsy, who are unable to walk without
crutches.Key words: Cerebral palsy, Whole-body vibration, Walking ability 相似文献
996.
Mitsuhiro Fujishiro Kazuhide Higuchi Mototsugu Kato Yoshikazu Kinoshita Ryuichi Iwakiri Toshio Watanabe Toshihisa Takeuchi Nobuyuki Sugisaki Yasushi Okada Hisao Ogawa Tetsuo Arakawa Kazuma Fujimoto the PLANETARIUM Study Group 《Journal of Clinical Biochemistry and Nutrition》2015,56(3):228-239
A 24-week, double-blind, clinical trial of rabeprazole for the prevention of
recurrent peptic ulcers caused by low-dose aspirin (LDA) has been reported, but
trials for longer than 24 weeks have not been reported. The aim of this study is to
assess the long-term efficacy and safety of rabeprazole for preventing peptic ulcer
recurrence on LDA therapy. Eligible patients had a history of peptic ulcers on
long-term LDA (81 or 100 mg/day) therapy. Patients with no recurrence of
peptic ulcers at the end of the 24-week double-blind phase with rabeprazole (10- or
5-mg once daily) or teprenone (50 mg three times daily) entered the extension
phase. Rabeprazole doses were maintained for a maximum of 76 weeks, including the
double-blind 24-week period and the extension phase period (long-term rabeprazole 10-
and 5-mg groups). Teprenone was randomly switched to rabeprazole 10 or 5 mg for
a maximum of 52 weeks in the extension phase (newly-initiated rabeprazole 10- and
5-mg groups). The full analysis set consisted of 151 and 150 subjects in the
long-term rabeprazole 10- and 5-mg groups, respectively, and the cumulative
recurrence rates of peptic ulcers were 2.2 and 3.7%, respectively. Recurrent
peptic ulcers were not observed in the newly-initiated rabeprazole 10- and 5-mg
groups. No bleeding ulcers were reported. No clinically significant safety findings,
including cardiovascular events, emerged. The use of long-term rabeprazole 10- and
5-mg once daily prevents the recurrence of peptic ulcers in subjects on low-dose
aspirin therapy, and both were well-tolerated. 相似文献
997.
Masaaki Mori Ryoji Kobayashi Koji Kato Naoko Maeda Keitaro Fukushima Hiroaki Goto Masami Inoue Chieko Muto Akifumi Okayama Kenichi Watanabe Ping Liu 《Antimicrobial agents and chemotherapy》2015,59(2):1004-1013
The aim of this study was to investigate the pharmacokinetics, safety, and tolerability of voriconazole following intravenous-to-oral switch regimens used with immunocompromised Japanese pediatric subjects (age 2 to <15 years) at high risk for systemic fungal infection. Twenty-one patients received intravenous-to-oral switch regimens based on a recent population pharmacokinetic modeling; they were given 9 mg/kg of body weight followed by 8 mg/kg of intravenous (i.v.) voriconazole every 12 h (q12h), and 9 mg/kg (maximum, 350 mg) of oral voriconazole q12h (for patients age 2 to <12 or 12 to <15 years and <50 kg) or 6 mg/kg followed by 4 mg/kg of i.v. voriconazole q12h and 200 mg of oral voriconazole q12h (for patients age 12 to <15 years and ≥50 kg). The steady-state area under the curve over the 12-h dosing interval (AUC0–12,ss) was calculated using the noncompartmental method and compared with the predicted exposures in Western pediatric subjects based on the abovementioned modeling. The geometric mean (coefficient of variation) AUC0–12,ss values for the intravenous and oral regimens were 51.1 μg · h/ml (68%) and 45.8 μg · h/ml (90%), respectively; there was a high correlation between AUC0–12,ss and trough concentration. Although the average exposures were higher in the Japanese patients than those in the Western pediatric subjects, the overall voriconazole exposures were comparable between these two groups due to large interindividual variability. The exposures in the 2 cytochrome P450 2C19 poor metabolizers were among the highest. Voriconazole was well tolerated. The most common treatment-related adverse events were photophobia and abnormal hepatic function. These recommended doses derived from the modeling appear to be appropriate for Japanese pediatric patients, showing no additional safety risks compared to those with adult patients. (This study has been registered at ClinicalTrials.gov under registration no. .) NCT01383993相似文献
998.
999.
Clinical outcomes of a novel therapeutic vaccine with Tax peptide‐pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study
下载免费PDF全文
![点击此处可从《British journal of haematology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Youko Suehiro Atsuhiko Hasegawa Tadafumi Iino Amane Sasada Nobukazu Watanabe Masao Matsuoka Ayako Takamori Ryuji Tanosaki Atae Utsunomiya Ilseung Choi Tetsuya Fukuda Osamu Miura Shigeo Takaishi Takanori Teshima Koichi Akashi Mari Kannagi Naokuni Uike Jun Okamura 《British journal of haematology》2015,169(3):356-367
Adult T cell leukaemia/lymphoma (ATL) is a human T cell leukaemia virus type‐I (HTLV‐I)‐infected T cell malignancy with poor prognosis. We herein developed a novel therapeutic vaccine designed to augment an HTLV‐I Tax‐specific cytotoxic T lymphocyte (CTL) response that has been implicated in anti‐ATL effects, and conducted a pilot study to investigate its safety and efficacy. Three previously treated ATL patients, classified as intermediate‐ to high‐risk, were subcutaneously administered with the vaccine, consisting of autologous dendritic cells (DCs) pulsed with Tax peptides corresponding to the CTL epitopes. In all patients, the performance status improved after vaccination without severe adverse events, and Tax‐specific CTL responses were observed with peaks at 16–20 weeks. Two patients achieved partial remission in the first 8 weeks, one of whom later achieved complete remission, maintaining their remission status without any additional chemotherapy 24 and 19 months after vaccination, respectively. The third patient, whose tumour cells lacked the ability to express Tax at biopsy, obtained stable disease in the first 8 weeks and later developed slowly progressive disease although additional therapy was not required for 14 months. The clinical outcomes of this pilot study indicate that the Tax peptide‐pulsed DC vaccine is a safe and promising immunotherapy for ATL. 相似文献
1000.